THE federal government on Thursday, 24, published a provisional measure to release around R $ 2.5 billion for the country to join the Covax Facility, a global consortium of governments and manufacturers to boost the development of vaccines against covid-19. In addition to this, a second measure, adhering to the program, was published in an extra edition of the Official Gazette of this Friday, 25.
“It is hoped that, through this instrument, Brazil will be able to buy the equivalent to guarantee the immunization of 10% of the population by the end of 2021, which allows it to serve populations considered to be priority”, states the Planalto Palace in a note. Membership will allow access to the portfolio of nine vaccines under development, in addition to others under analysis.
The government is betting on the vaccine developed by the University of Oxford and AstraZeneca against covid-19. Fiocruz received an investment of R $ 2 billion to receive, process, distribute and start to manufacture the immunizer alone. The idea is that the first 15 million doses are applied in January 2021 in Brazil, a year in which 100 million units are to be distributed.
The Minister of Health, Eduardo Pazuello, said on Thursday, 24, that the folder follows the development of all vaccines, and does not rule out buying doses beyond those of Oxford.
State governments also have their own vaccine negotiations. São Paulo, for example, bets on Coronavac, made in China. Paraná, in turn, has negotiations with Russia to manufacture Sputnik V.
“This initiative (joining the Covax Facility) does not prevent the country from subsequently entering into bilateral agreements with other biopharmaceutical companies producing vaccines against Covid-19 that are not covered by the global initiative. Nor are initiatives already carried out by the Brazilian State, with biopharmaceutical companies that are part of the global initiative, ”said Planalto in a note.